Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib adjuvant therapy after radical hepatectomy for hepatocellular carcinoma
ChiCTR2100048460Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Hunan Cancer Hospital. Primary endpoint: 1-year cumulative recurrence-free survival rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100048460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048460.